Roche Holding AG plans to buy Spark Therapeutics Inc for US$4.8 billion, a deal that would give the Swiss drugmaker one of the first-ever therapies to treat, and potentially cure, a disease by providing a fix for a patient’s defective genes.
Roche is to pay US$114.50 a share for Philadelphia-based Spark, a 122 percent premium to the biotechnology company’s close in New York trading on Friday.
While the price is rich, Spark shares were trading above US$90 as recently as last year.
The offer was a 19 percent premium to Spark’s 52-week intraday high, Roche said.
Along with French biopharmaceutical company Ipsen SA’s agreement yesterday to acquire Clementia Pharmaceuticals Inc for as much as US$1.3 billion, the Roche deal shows how drug companies are placing big bets on the fraught but lucrative field of rare diseases.
Gene therapies, in particular, are a promising new area of medicine with the potential to cure a wide range of often-rare diseases by replacing or repairing errors in the body’s instruction manual.
Their amazing potential has been matched by breakthrough prices, as companies have sought to charge hundreds of thousands of dollars for them — or more.
The Roche deal’s premium is an outlier, but recent pharmaceutical deals have come with rich valuations.
Acquirers paid an average 45 percent premium in takeovers of listed pharmaceutical and biotechnology companies announced over the past five years, data compiled by Bloomberg show.
Spark’s therapy Luxturna treats a gene-driven form of blindness by injecting a working version of a gene called RPE65. In people with that condition, the working genes can help restore sight.
After Luxturna was approved by US regulators in 2017, Spark said it would charge US$425,000 per eye for the treatment.
Spark was founded in 2013 at Children’s Hospital of Philadelphia. Along with Luxturna, it is developing gene therapies for the bleeding disorder hemophilia, an area where Roche is seeking to broaden its presence.
Spark already has a licensing agreement with Roche’s crosstown rival, Basel-based Novartis AG. Under an agreement struck last year, Novartis has the rights to sell Luxturna outside the US.
ENERGY ISSUES: The TSIA urged the government to increase natural gas and helium reserves to reduce the impact of the Middle East war on semiconductor supply stability Chip testing and packaging service provider ASE Technology Holding Co (日月光投控) yesterday said it planned to invest more than NT$100 billion (US$3.15 billion) in building a new advanced chip testing facility in Kaohsiung to keep up with customer demand driven by the artificial intelligence (AI) boom. That would be included in the company’s capital expenditure budget next year, ASE said. There is also room to raise this year’s capital spending budget from a record-high US$7 billion estimated three months ago, it added. ASE would have six factories under construction this year, another record-breaking number, ASE chief operating officer Tien Wu
The EU and US are nearing an agreement to coordinate on producing and securing critical minerals, part of a push to break reliance on Chinese supplies. The potential deal would create incentives, such as minimum prices, that could advantage non-Chinese suppliers, according to a draft of an “action plan” seen by Bloomberg. The EU and US would also cooperate on standards, investments and joint projects, as well as coordinate on any supply disruptions by countries like China. The two sides are additionally seeking other “like-minded partners” to join a multicountry accord to help create these new critical mineral supply chains, which feed into
For weeks now, the global tech industry has been waiting for a major artificial intelligence (AI) launch from DeepSeek (深度求索), seen as a benchmark for China’s progress in the fast-moving field. More than a year has passed since the start-up put Chinese AI on the map in early last year with a low-cost chatbot that performed at a similar level to US rivals. However, despite reports and rumors about its imminent release, DeepSeek’s next-generation “V4” model is nowhere in sight. Speculation is also swirling over the geopolitical implications of which computer chips were chosen to train and power the new
TECH WINNERS: Taiwan and South Korea reported robust trade, which suggests that they have critical advantages in the rapidly expanding AI supply chain, an official said Exports last month surged to a new high, as booming demand tied to artificial intelligence (AI) infrastructure fueled shipments of advanced technology components, underscoring the nation’s pivotal role in the global semiconductor supply chain. Outbound shipments climbed to US$80.18 billion, the highest ever for a single month, rising 61.8 percent from a year earlier and marking the 29th consecutive month of growth, the Ministry of Finance said yesterday. “The surge was driven primarily by global investment in AI infrastructure,” Department of Statistics Director-General Beatrice Tsai (蔡美娜) said. The mass production of next-generation AI computing systems has accelerated procurement across the semiconductor supply
RSS